WallStSmart

Johnson & Johnson (JNJ)vsAlaunos Therapeutics Inc (TCRT)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Johnson & Johnson generates 3311166433% more annual revenue ($99.33B vs $3,000). JNJ leads profitability with a 16.2% profit margin vs 0.0%. TCRT appears more attractively valued with a PEG of 0.58. JNJ earns a higher WallStSmart Score of 54/100 (C-).

JNJ

Buy

54

out of 100

Grade: C-

Growth: 4.7Profit: 8.5Value: 3.7Quality: 5.5
Piotroski: 3/9Altman Z: 2.64

TCRT

Avoid

24

out of 100

Grade: F

Growth: 2.7Profit: 2.5Value: 6.0Quality: 3.3
Piotroski: 2/9Altman Z: -439.02

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

JNJ3 strengths · Avg: 8.7/10
Market CapQuality
$682.52B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
26.6%8/10

Strong operational efficiency at 26.6%

Free Cash FlowQuality
$6.36B8/10

Generating 6.4B in free cash flow

TCRT1 strengths · Avg: 8.0/10
PEG RatioValuation
0.588/10

Growing faster than its price suggests

Areas to Watch

JNJ4 concerns · Avg: 2.8/10
Price/BookValuation
8.4x4/10

Trading at 8.4x book value

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
3.162/10

Expensive relative to growth rate

P/E RatioValuation
43.0x2/10

Premium valuation, high expectations priced in

TCRT4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$5.99M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : JNJ

The strongest argument for JNJ centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 16.2% and operating margin at 26.6%.

Bull Case : TCRT

The strongest argument for TCRT centers on PEG Ratio. PEG of 0.58 suggests the stock is reasonably priced for its growth.

Bear Case : JNJ

The primary concerns for JNJ are Price/Book, Piotroski F-Score, PEG Ratio. A P/E of 43.0x leaves little room for execution misses.

Bear Case : TCRT

The primary concerns for TCRT are EPS Growth, Market Cap, Profit Margin.

Key Dynamics to Monitor

JNJ profiles as a mature stock while TCRT is a value play — different risk/reward profiles.

JNJ carries more volatility with a beta of 0.20 — expect wider price swings.

JNJ is growing revenue faster at 5.9% — sustainability is the question.

JNJ generates stronger free cash flow (6.4B), providing more financial flexibility.

Bottom Line

JNJ scores higher overall (54/100 vs 24/100), backed by strong 16.2% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Johnson & Johnson

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.

Visit Website →

Alaunos Therapeutics Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Alaunos Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on discovering, acquiring, developing and commercializing a portfolio of immuno-oncology therapies to treat cancer patients. The company is headquartered in Houston, Texas.

Visit Website →

Want to dig deeper into these stocks?